A Controlled, Randomised, Parallel, Multicentre Study to Assess Safety and Tolerability of the Oral Direct Thrombin Inhibitor AZD0837 in the Prevention of Stroke and other Thromboembolic Complications Associated with Atrial Fibrillation.
Phase of Trial: Phase II
Latest Information Update: 28 Sep 2015
At a glance
- Drugs AZD 0837 (Primary) ; Warfarin
- Indications Stroke; Thromboembolism
- Focus Adverse reactions
- Sponsors AstraZeneca
- 05 Nov 2010 New trial record.